ERBB2 and breast adenocarcinoma: The cell-ELISA profiles therefore serve to validate the retained selective binding-avidity of gemcitabine-(C4-amide)-[anti-HER2/neu] for HER2/neu receptor sites highly over-expressed at 1×106/cell on the exterior surface membrane of mammary adenocarcinoma (SKBr-3) populations (Figure 3) [22].